|[February 03, 2014]
Ignyta Appoints Matthew Onaitis as General Counsel
SAN DIEGO --(Business Wire)--
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine
biotechnology company, announced today that Matthew Onaitis has been
appointed to the newly created role of General Counsel and Secretary.
Mr. Onaitis was previously Senior Vice President, General Counsel and
Secretary of Trius Therapeutics, Inc., where he led the legal and
compliance functions through Trius' acquisition by Cubist
Pharmaceuticals, Inc. in September 2013. Mr. Onaitis assisted Cubist
with integration activities through December 2013. Prior to Trius, Mr.
Onaitis was Senior Vice President, General Counsel and Secretary of
Somaxon Pharmaceuticals, Inc. from 2006 until Somaxon's acquisition by
Pernix Therapeutics Holdings, Inc. in March 2013. Mr. Onaitis also
previously served as Associate General Counsel for the oncology
strategic business unit of Biogen Idec Inc. and as Director of Legal
Affairs of Elan Corporation, plc.
"Matt has broad legal experience with development-stage and
publicly-traded, commercial-stage biopharmaceutical companies," said
Jonathan Lim, M.D., Chairman and CEO of Ignyta. "In particular, his
background in managing corporate governance and compliance programs,
supporting operational teams, and advising on various business
transactions will strengthen our management team as we strive to create
value for patients with our proprietary oncology drug candidates and our
integrated Rx/Dx discovery approach."
About Ignyta, Inc.
Ignyta, Inc., located in San Diego, Clifornia, is a biotechnology
company developing precision medicine with integrated Rx/Dx solutions
for cancer patients. Our goal is to discover and develop revolutionary
new drugs that target activated genes in cancer cells for the customized
treatment of cancer patients. Our present focus is on the development of
RXDX-101 and RXDX-102, our proprietary oral tyrosine kinase inhibitors
that target solid tumor indications, and advancing our novel Spark
discovery programs that leverage our proprietary cancer genomic and
epigenomic knowledge bases. For more information, please visit: www.ignyta.com.
This press release contains forward-looking statements as that term is
defined in Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Statements in this press release
that are not purely historical are forward-looking statements. Such
forward-looking statements include, among other things, references to
novel technologies and methods; our progress in developing new oncology
therapies; our business and product development plans; and market
information. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, our ability to retain important members of our
management team and attract other qualified personnel; our ability to
raise the additional funding we will need to continue to pursue our
business and product development plans; the inherent uncertainties
associated with developing new products or technologies and operating as
a development stage company; our ability to develop, complete clinical
trials for, obtain approvals for and commercialize any of our product
candidates; competition in the industry in which we operate and market
conditions. These forward-looking statements are made as of the date of
this press release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual results
could differ from those projected in the forward-looking statements.
Investors should consult all of the information set forth herein and
should also refer to the risk factor disclosure set forth in the reports
and other documents we file with the SEC (News - Alert) available at www.sec.gov,
including without limitation our Current Report on Form 8-K dated
October 31, 2013 and amended November 14, 2013 and December 9, 2013.
[ Back To TMCnet.com's Homepage ]